Relievant Medsystems Inc., a Redwood City, Calif.-based medical device company focused on basivertebral nerve ablation for the treatment of chronic axial low back pain, has raised $30m in Series D financing.
The round was led by New Enterprise Associates, with participation from existing investors Canaan Partners, Emergent Medical Partners, Morgenthaler Ventures and ONSET Ventures.
The company intends to use the funding to advance and expand its worldwide clinical development programs (http://www.smartclinicalstudy.com).
In conjunction with the funding, NEA Partner Justin Klein, M.D., has joined Relievant’s Board of Directors.
Led by CEO and President Alex DiNello, Relievant is developing the Intracept System, a minimally invasive procedure that uses radiofrequency energy delivered via percutaneous access into the vertebral body of the spine to ablate the basivertebral nerve.